DiversimAb™ mice provide an advantage in nearly any custom antibody discovery application due to the increased epitopic diversity of the mAbs generated. As a benefit of enhanced antibody diversities, the DiversimAb™ platform readily enables the discovery of species' cross-reactive antibodies, including human, cyno, and mouse cross-reactive antibodies.

Our auto-immune, hyperimmune model enables the delivery of antibodies against difficult targets, including cell surface receptors and epitopes that do not elicit a robust immune response in natural mice. We've delivered antibodies against 100% Mus musculus proteins using DiversimAb™ mice.

Twist uses proprietary, customizable immunization protocols optimized for DiversimAb™ for multipass membrane proteins including GPCRs, ion channels, high-homology targets, and poor immunogens. These rapid immunization strategies can elicit robust immune responses in weeks rather than months, delivering leads without sacrificing affinity or quality.

Twist offers royalty-free, flexible business models, including fee-for-service and partnership structures, to access our DiversimAb™ platform for your most challenging targets and high-profile programs.